Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation

Stroke is a common, debilitating trauma that has an incompletely elucidated pathophysiology and lacks an effective therapy. FoxP3+CD25+CD4+ regulatory T cells (Tregs) suppress a variety of normal physiological and pathological immune responses via several pathways, such as inhibitory cytokine secret...

Full description

Saved in:
Bibliographic Details
Main Authors: Sheng Chen, Haijian Wu, Damon Klebe, Yuan Hong, Jianmin Zhang, Jiping Tang
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:Clinical and Developmental Immunology
Online Access:http://dx.doi.org/10.1155/2013/689827
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850178620261138432
author Sheng Chen
Haijian Wu
Damon Klebe
Yuan Hong
Jianmin Zhang
Jiping Tang
author_facet Sheng Chen
Haijian Wu
Damon Klebe
Yuan Hong
Jianmin Zhang
Jiping Tang
author_sort Sheng Chen
collection DOAJ
description Stroke is a common, debilitating trauma that has an incompletely elucidated pathophysiology and lacks an effective therapy. FoxP3+CD25+CD4+ regulatory T cells (Tregs) suppress a variety of normal physiological and pathological immune responses via several pathways, such as inhibitory cytokine secretion, direct cytolysis induction, and antigen-presenting cell functional modulation. FoxP3+CD25+CD4+ Tregs are involved in a variety of central nervous system diseases and injuries, including axonal injury, neurodegenerative diseases, and stroke. Specifically, FoxP3+CD25+CD4+ Tregs exert neuroprotective effects in acute experimental stroke models. These beneficial effects, however, are difficult to elucidate. In this review, we summarized evidence of FoxP3+CD25+CD4+ Tregs as potentially important immunomodulators in stroke pathogenesis and highlight further investigations for possible immunotherapeutic strategies by modulating the quantity and/or functional effects of FoxP3+CD25+CD4+ Tregs in stroke patients.
format Article
id doaj-art-bbc3bc7ec0f445d1956d533cbc3603ec
institution OA Journals
issn 1740-2522
1740-2530
language English
publishDate 2013-01-01
publisher Wiley
record_format Article
series Clinical and Developmental Immunology
spelling doaj-art-bbc3bc7ec0f445d1956d533cbc3603ec2025-08-20T02:18:42ZengWileyClinical and Developmental Immunology1740-25221740-25302013-01-01201310.1155/2013/689827689827Regulatory T Cell in Stroke: A New Paradigm for Immune RegulationSheng Chen0Haijian Wu1Damon Klebe2Yuan Hong3Jianmin Zhang4Jiping Tang5Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92350, USADepartment of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, ChinaDepartment of Physiology and Pharmacology, Loma Linda University, Loma Linda, CA 92350, USAStroke is a common, debilitating trauma that has an incompletely elucidated pathophysiology and lacks an effective therapy. FoxP3+CD25+CD4+ regulatory T cells (Tregs) suppress a variety of normal physiological and pathological immune responses via several pathways, such as inhibitory cytokine secretion, direct cytolysis induction, and antigen-presenting cell functional modulation. FoxP3+CD25+CD4+ Tregs are involved in a variety of central nervous system diseases and injuries, including axonal injury, neurodegenerative diseases, and stroke. Specifically, FoxP3+CD25+CD4+ Tregs exert neuroprotective effects in acute experimental stroke models. These beneficial effects, however, are difficult to elucidate. In this review, we summarized evidence of FoxP3+CD25+CD4+ Tregs as potentially important immunomodulators in stroke pathogenesis and highlight further investigations for possible immunotherapeutic strategies by modulating the quantity and/or functional effects of FoxP3+CD25+CD4+ Tregs in stroke patients.http://dx.doi.org/10.1155/2013/689827
spellingShingle Sheng Chen
Haijian Wu
Damon Klebe
Yuan Hong
Jianmin Zhang
Jiping Tang
Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation
Clinical and Developmental Immunology
title Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation
title_full Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation
title_fullStr Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation
title_full_unstemmed Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation
title_short Regulatory T Cell in Stroke: A New Paradigm for Immune Regulation
title_sort regulatory t cell in stroke a new paradigm for immune regulation
url http://dx.doi.org/10.1155/2013/689827
work_keys_str_mv AT shengchen regulatorytcellinstrokeanewparadigmforimmuneregulation
AT haijianwu regulatorytcellinstrokeanewparadigmforimmuneregulation
AT damonklebe regulatorytcellinstrokeanewparadigmforimmuneregulation
AT yuanhong regulatorytcellinstrokeanewparadigmforimmuneregulation
AT jianminzhang regulatorytcellinstrokeanewparadigmforimmuneregulation
AT jipingtang regulatorytcellinstrokeanewparadigmforimmuneregulation